THRN — Thorne HealthTech Share Price
- $550.63m
- $563.26m
- $228.73m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 13.35 | ||
PEG Ratio (f) | 0.37 | ||
EPS Growth (f) | 57.56% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.29 | ||
Price to Tang. Book | 3.01 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.41 | ||
EV to EBITDA | 48.79 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 0.33% | ||
Return on Equity | 7.54% | ||
Operating Margin | 0.29% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | 102.53 | 138.45 | 184.3 | 228.73 | 282.13 | 360.95 | 30.66% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | +191.68 | -3.46 | +105.8 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Thorne HealthTech, Inc. is a science-driven wellness company that is developing solutions for a personalized approach to health and wellness. The Company’s vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products and services that individuals to take a proactive approach to improve and maintain their health over their lifetime. By combining its multi-omics database, artificial intelligence (AI) and digital health content with its science-backed nutritional supplements, it delivers a total system for wellness. Thorne provides health tests, education, and products that support the optimization of health. Onegevity provides a comprehensive molecular portrait and personalized recommendations for an individual’s health, based on integrated analysis of longitudinal blood, genetics and gut microbiome profiles. It offers health tests to generate comprehensive, personalized molecular portraits for its customers.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- June 17th, 2010
- Public Since
- September 23rd, 2021
- No. of Shareholders
- 64
- No. of Employees
- 544
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 53,858,273
- Address
- 620 Omni Industrial Blvd., SUMMERVILLE, 29483
- Web
- https://investors.thornehealthtech.com/overview/
- Phone
- +1 8435010286
- Auditors
- BDO USA, LLP
Upcoming Events for THRN
Similar to THRN
Abcam
NASDAQ Global Select Market
Acelyrin
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 01:23 UTC, shares in Thorne HealthTech are trading at $6.26. This share price information is delayed by 15 minutes.
Shares in Thorne HealthTech last closed at $6.26 and the price had moved by +23.23% over the past 365 days. In terms of relative price strength the Thorne HealthTech share price has outperformed the S&P500 Index by +5.79% over the past year.
The overall consensus recommendation for Thorne HealthTech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThorne HealthTech does not currently pay a dividend.
Thorne HealthTech does not currently pay a dividend.
Thorne HealthTech does not currently pay a dividend.
To buy shares in Thorne HealthTech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.26, shares in Thorne HealthTech had a market capitalisation of $317.23m.
Here are the trading details for Thorne HealthTech:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: THRN
Based on an overall assessment of its quality, value and momentum Thorne HealthTech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Thorne HealthTech is $7.44. That is 18.85% above the last closing price of $6.26.
Analysts covering Thorne HealthTech currently have a consensus Earnings Per Share (EPS) forecast of $0.29 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thorne HealthTech. Over the past six months, its share price has outperformed the S&P500 Index by +34.43%.
As of the last closing price of $6.26, shares in Thorne HealthTech were trading +38.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Thorne HealthTech PE ratio based on its reported earnings over the past 12 months is 13.35. The shares last closed at $6.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Thorne HealthTech's directors